메뉴 건너뛰기




Volumn 118, Issue 9, 2012, Pages 2403-2410

Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: A 2-cohort, phase 2 study

Author keywords

eribulin; ovarian cancer; phase 2; recurrence

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERIBULIN; GEMCITABINE; PACLITAXEL; PEMETREXED; PLATINUM; TOPOTECAN;

EID: 84860217796     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26569     Document Type: Article
Times cited : (20)

References (19)
  • 2
    • 0032977940 scopus 로고    scopus 로고
    • Natural history of stage IV epithelial ovarian cancer
    • Bonnefoi H, A'Hern RP, Fisher C, et al. Natural history of stage IV epithelial ovarian cancer. J Clin Oncol. 1999; 17: 767-775.
    • (1999) J Clin Oncol , vol.17 , pp. 767-775
    • Bonnefoi, H.1    A'Hern, R.P.2    Fisher, C.3
  • 3
    • 0030054309 scopus 로고    scopus 로고
    • Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
    • McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996; 334: 1-6.
    • (1996) N Engl J Med , vol.334 , pp. 1-6
    • McGuire, W.P.1    Hoskins, W.J.2    Brady, M.F.3
  • 5
    • 0035110756 scopus 로고    scopus 로고
    • In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B
    • Towle MJ, Salvato KA, Budrow J, et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. 2001; 61: 1013-1021.
    • (2001) Cancer Res , vol.61 , pp. 1013-1021
    • Towle, M.J.1    Salvato, K.A.2    Budrow, J.3
  • 6
    • 0034594628 scopus 로고    scopus 로고
    • New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    • Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
    • (2000) J Natl Cancer Inst , vol.92 , pp. 205-216
    • Therasse, P.1    Arbuck, S.G.2    Eisenhauer, E.A.3
  • 7
    • 0029961618 scopus 로고    scopus 로고
    • Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125
    • Rustin GJ, Nelstrop AE, McClean P, et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol. 1996; 5: 1545-1551.
    • (1996) J Clin Oncol , vol.5 , pp. 1545-1551
    • Rustin, G.J.1    Nelstrop, A.E.2    McClean, P.3
  • 8
    • 2542638781 scopus 로고    scopus 로고
    • Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer
    • Rustin GJ, Bast RC Jr, Kelloff GJ, et al. Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin Cancer Res. 2004; 10: 3919-3926.
    • (2004) Clin Cancer Res , vol.10 , pp. 3919-3926
    • Rustin, G.J.1    Bast, Jr.R.C.2    Kelloff, G.J.3
  • 9
    • 0024536437 scopus 로고
    • Optimal 2-stage designs for phase II clinical trials
    • Simon R,. Optimal 2-stage designs for phase II clinical trials. Control Clin Trials. 1989; 10: 1-10.
    • (1989) Control Clin Trials , vol.10 , pp. 1-10
    • Simon, R.1
  • 10
    • 48049090687 scopus 로고    scopus 로고
    • Proper inference from Simon's 2-stage designs
    • Koyama T, Chen H,. Proper inference from Simon's 2-stage designs. Stat Med. 2008; 27: 3145-3154.
    • (2008) Stat Med , vol.27 , pp. 3145-3154
    • Koyama, T.1    Chen, H.2
  • 11
    • 33845382806 scopus 로고
    • Nonparametric estimation from incomplete observations
    • Kaplan EL, Meier P,. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
    • (1958) J Am Stat Assoc , vol.53 , pp. 457-481
    • Kaplan, E.L.1    Meier, P.2
  • 13
    • 0035879099 scopus 로고    scopus 로고
    • Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan
    • Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001; 19: 3312-3322.
    • (2001) J Clin Oncol , vol.19 , pp. 3312-3322
    • Gordon, A.N.1    Fleagle, J.T.2    Guthrie, D.3
  • 14
    • 34447570846 scopus 로고    scopus 로고
    • Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer
    • Mutch DG, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2007; 25: 2811-2818.
    • (2007) J Clin Oncol , vol.25 , pp. 2811-2818
    • Mutch, D.G.1    Orlando, M.2    Goss, T.3
  • 15
    • 0033813383 scopus 로고    scopus 로고
    • 2) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum
    • 2) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol Oncol. 2000; 78 (3 pt 1): 369-372.
    • (2000) Gynecol Oncol , vol.78 , Issue.3 PART 1 , pp. 369-372
    • Markman, M.1    Kennedy, A.2    Webster, K.3
  • 16
    • 0033850066 scopus 로고    scopus 로고
    • Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer
    • Gordon AN, Granai CO, Rose PG, et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol. 2000; 18: 3093-3100.
    • (2000) J Clin Oncol , vol.18 , pp. 3093-3100
    • Gordon, A.N.1    Granai, C.O.2    Rose, P.G.3
  • 17
    • 77955893812 scopus 로고    scopus 로고
    • A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane [abstract]
    • on behalf of the Study 305 investigators.:. Abstract CRA1004.
    • Twelves C, Loesch D, Blum JL, et al. on behalf of the Study 305 investigators. A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane [abstract]. J Clin Oncol. 2010; 28: 18S. Abstract CRA1004.
    • (2010) J Clin Oncol , vol.28
    • Twelves, C.1    Loesch, D.2    Blum, J.L.3
  • 18
    • 77957594393 scopus 로고    scopus 로고
    • Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine
    • Cortes J, Vahdat L, Blum JL, et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2010; 28: 3922-3928.
    • (2010) J Clin Oncol , vol.28 , pp. 3922-3928
    • Cortes, J.1    Vahdat, L.2    Blum, J.L.3
  • 19
    • 70949093173 scopus 로고    scopus 로고
    • Consolidation strategies in ovarian cancer: Observations for future clinical trials
    • Sabbatini P, Spriggs D, Aghajanian C, et al. Consolidation strategies in ovarian cancer: observations for future clinical trials. Gynecol Oncol. 2010; 116: 66-71.
    • (2010) Gynecol Oncol , vol.116 , pp. 66-71
    • Sabbatini, P.1    Spriggs, D.2    Aghajanian, C.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.